173 related articles for article (PubMed ID: 29207031)
1. PRL‑3 increases the aggressive phenotype of prostate cancer cells in vitro and its expression correlates with high-grade prostate tumors in patients.
Edwards DR; Moroz K; Zhang H; Mulholland D; Abdel-Mageed AB; Mondal D
Int J Oncol; 2018 Feb; 52(2):402-412. PubMed ID: 29207031
[TBL] [Abstract][Full Text] [Related]
2. PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
Carleton NM; Zhu G; Gorbounov M; Miller MC; Pienta KJ; Resar LMS; Veltri RW
Prostate; 2018 May; 78(7):547-559. PubMed ID: 29520928
[TBL] [Abstract][Full Text] [Related]
3. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression.
Barboro P; Salvi S; Rubagotti A; Boccardo S; Spina B; Truini M; Carmignani G; Introini C; Ferrari N; Boccardo F; Balbi C
Int J Oncol; 2014 May; 44(5):1589-98. PubMed ID: 24626777
[TBL] [Abstract][Full Text] [Related]
5. Correlation of PRL3 expression with colorectal cancer progression.
Leiphrakpam PD; Lazenby AJ; Smith LM; Brattain MG; Black JD; Wang J; Are C
J Surg Oncol; 2021 Jan; 123(1):42-51. PubMed ID: 33179291
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
7. Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.
Ambrosio MR; Di Serio C; Danza G; Rocca BJ; Ginori A; Prudovsky I; Marchionni N; Del Vecchio MT; Tarantini F
Diagn Pathol; 2016 May; 11(1):45. PubMed ID: 27225200
[TBL] [Abstract][Full Text] [Related]
8. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
9. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer.
Koike H; Sekine Y; Kamiya M; Nakazato H; Suzuki K
Urology; 2008 Dec; 72(6):1229-33. PubMed ID: 18336887
[TBL] [Abstract][Full Text] [Related]
10. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
12. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
[TBL] [Abstract][Full Text] [Related]
13. Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy.
Xu XF; Zhou SW; Zhang X; Ye ZQ; Zhang JH; Ma X; Zheng T; Li HZ
Asian J Androl; 2006 Jul; 8(4):455-62. PubMed ID: 16763722
[TBL] [Abstract][Full Text] [Related]
14. Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
Falegan OS; Jarvi K; Vogel HJ; Hyndman ME
Prostate; 2021 Aug; 81(11):713-720. PubMed ID: 34097313
[TBL] [Abstract][Full Text] [Related]
15. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
Sinha AA; Quast BJ; Korkowski JC; Wilson MJ; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
[TBL] [Abstract][Full Text] [Related]
16. Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2.
Kroiss A; Vincent S; Decaussin-Petrucci M; Meugnier E; Viallet J; Ruffion A; Chalmel F; Samarut J; Allioli N
Oncogene; 2015 May; 34(22):2846-55. PubMed ID: 25065599
[TBL] [Abstract][Full Text] [Related]
17. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
19. Expression of the cancer-testis antigen BORIS correlates with prostate cancer.
Cheema Z; Hari-Gupta Y; Kita GX; Farrar D; Seddon I; Corr J; Klenova E
Prostate; 2014 Feb; 74(2):164-76. PubMed ID: 24123052
[TBL] [Abstract][Full Text] [Related]
20. Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.
Barquilha CN; Santos NJ; Monção CCD; Barbosa IC; Lima FO; Justulin LA; Pértega-Gomes N; Felisbino SL
Oxid Med Cell Longev; 2020; 2020():2148562. PubMed ID: 32411320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
